US2018353466A1PendingUtilityA1

Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer

Assignee: RES INSTITUTE FOR NUTRITION AND AGING CO LTDPriority: May 24, 2013Filed: Aug 21, 2018Published: Dec 13, 2018

Est. expiryMay 24, 2033(~6.9 yrs left)· nominal 20-yr term from priority

Inventors:Kunihiko Kiyono Kenji Onishi Yasuharu Nagahama Takashi Watanabe

A61P 43/00A61P 35/02A61P 35/00A61P 1/18A61K 31/155A61K 45/06A61K 31/353A61K 2300/00A61K 31/352

PatentIndex Score

Cited by

References

Claims

Abstract

Provided is a novel medicament capable of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof and useful as an anti-malignant tumor agent, in which metformin or a pharmaceutically acceptable salt thereof and dihydroquercetin or a pharmaceutically acceptable salt thereof are combined.

Claims

exact text as granted — not AI-modified

1 - 27 . (canceled) 
     
     
         28 . A method of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof, comprising administering dihydroquercetin or a pharmaceutically acceptable salt thereof to a patient with a malignant tumor. 
     
     
         29 . A method of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof, comprising administering dihydroquercetin or a pharmaceutically acceptable salt thereof, in combination with metformin or a pharmaceutically acceptable salt thereof, to a patient with a malignant tumor.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.